NU Skin Enterprises, Inc. key statistics and ratios

In fiscal 2025, NU Skin Enterprises, Inc. had return on equity of 22.0%, an operating margin of 4.4%, debt equal to 27.9% of equity and a current ratio of 2.08. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

NU Skin Enterprises, Inc.: financial ratios, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	81.7%	82.3%	81.2%	83.4%	84.1%	81.4%	78.2%	77.3%	78.0%	76.3%	76.0%	74.5%	75.0%	71.7%	68.9%	68.2%	69.4%	69.2%
Operating margin	11.1%	14.1%	13.6%	16.0%	17.4%	13.7%	10.9%	10.5%	12.0%	9.0%	11.0%	10.0%	8.7%	5.0%	2.5%	−8.8%	4.4%	−0.8%
Net margin	6.7%	8.9%	8.9%	10.4%	11.5%	7.4%	5.9%	6.5%	5.7%	4.5%	7.2%	7.4%	5.5%	4.7%	0.4%	−8.5%	10.8%	−15.7%
Free-cash-flow margin	8.5%	8.7%	10.6%	10.1%	10.9%	−6.1%	11.8%	10.2%	10.6%	4.9%	4.6%	12.2%	2.7%	2.2%	3.1%	4.1%	3.1%	0.8%
Return on equity	23.9%	32.1%	29.3%	38.1%	50.4%	21.0%	15.1%	19.2%	18.9%	16.4%	20.9%	21.6%	16.3%	11.6%	1.0%	−19.9%	22.0%	−32.1%
Return on assets	12.0%	16.6%	16.3%	21.0%	24.8%	11.0%	8.5%	9.6%	8.4%	7.4%	10.0%	10.3%	7.6%	5.6%	0.5%	−8.9%	11.1%	−17.1%
Asset turnover	1.78	1.87	1.83	2.02	2.16	1.50	1.44	1.48	1.49	1.63	1.40	1.39	1.40	1.19	1.08	1.06	1.03	1.09
Current ratio	1.82	1.95	2.20	1.84	1.44	2.00	1.73	1.79	1.74	1.82	2.07	1.66	1.65	2.12	2.13	1.82	2.08	1.98
Debt to equity	41.7%	34.1%	23.8%	32.8%	21.2%	26.8%	30.8%	65.5%	57.0%	55.6%	41.7%	37.7%	41.2%	44.9%	61.4%	60.6%	27.9%	39.4%
Interest cover (operating income ÷ interest)	21.4x	37.4x	48.7x	65.5x	184.7x	61.8x	31.0x	14.8x	12.4x	11.0x	13.9x	19.7x	21.3x	8.2x	1.9x	n/m	4.7x	n/m
Effective tax rate	36.3%	34.5%	32.4%	35.8%	34.5%	36.6%	37.2%	32.8%	51.3%	44.5%	32.0%	25.3%	36.6%	−17.8%	67.7%	—	18.3%	—
R&D as % of revenue	0.8%	0.8%	0.8%	0.7%	0.6%	0.7%	0.9%	1.1%	1.0%	0.9%	1.2%	0.9%	1.0%	1.0%	1.1%	0.8%	0.7%	—
Capital spending as % of revenue	1.5%	3.5%	2.4%	4.5%	5.8%	3.9%	2.5%	2.3%	2.6%	2.6%	2.7%	2.5%	2.5%	2.7%	3.0%	2.4%	2.3%	2.9%
Free cash flow ÷ net income	126.6%	98.6%	119.0%	96.7%	94.6%	−83.5%	199.5%	157.3%	187.3%	108.6%	64.5%	164.8%	49.5%	46.8%	699.8%	—	28.7%	—
Dividends ÷ net income	32.3%	22.9%	23.9%	21.8%	19.3%	43.0%	61.0%	54.8%	58.8%	66.1%	47.4%	41.0%	51.8%	73.5%	903.1%	—	7.4%	—
Dividends and buybacks ÷ free cash flow	44.1%	66.9%	56.9%	116.6%	61.3%	—	92.4%	144.7%	61.0%	113.4%	74.2%	70.6%	214.7%	300.1%	150.7%	17.0%	69.3%	294.0%

US$ thousands unless shown otherwise. Fiscal quarters.

NU Skin Enterprises, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	70.1%	62.7%	67.8%	68.8%	70.5%	70.7%	66.9%	68.2%
Operating margin	4.2%	−11.9%	−2.7%	8.0%	5.9%	6.3%	1.3%	−18.5%
Net margin	1.9%	−8.1%	29.5%	5.5%	4.7%	3.9%	0.6%	−78.0%
Free-cash-flow margin	5.3%	3.0%	−3.6%	9.3%	4.8%	1.6%	−5.5%	1.6%
Current ratio	1.93	1.82	2.02	2.01	2.15	2.08	2.03	1.98
Debt to equity	61.3%	60.4%	31.7%	31.6%	28.6%	27.8%	28.2%	39.4%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 7 checks passed · June 30, 2026

What it owns · $1.1bn

Short-term assets $508mLonger-term assets $613m

What it owes, and who funded it · $1.1bn

Short-term liabilities $256mLonger-term liabilities $322mShareholders' equity $543m

Short-term assets cover short-term liabilities $508m of assets due within a year against $256m of liabilities due within a year.
Short-term assets cover long-term liabilities $508m short-term assets against $322m of longer-dated liabilities.
More cash than debt $190m of cash against $214m of debt.
Debt below 40% of shareholders' equity Debt is 39% of equity.
Debt burden no higher than five years ago Debt to equity moved from 29% to 39% over five years.
A year's operating cash flow covers at least 20% of debt $51m of operating cash flow against $214m of debt.
Operating profit covers interest at least five times over Operating income of −$10m against $16m of interest.

From NU Skin Enterprises, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

55 /100

Moderate moat

How hard NU Skin Enterprises's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 10 / 20

Net income has been a median 7.0% of total assets over 10 years.
Pricing power 18 / 20

Gross margin has been a median 74.3%, moving by 3.9 percentage points (standard deviation) across 10 years.
Durability 1 / 20

Operating margin has been a median 8.5%; its worst year was -6.9%.
Cash conversion 13 / 20

Free cash flow was positive in 10 of 10 years, at a median 5.8% of revenue.
Discipline 18 / 20

The diluted share count fell 4.0% over five years; stock-based pay has been a median 0.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (60 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IPAR vs NUS ELF vs NUS NUS vs USNA NUS vs ODD

More: Personal Care Products stocks compared, Consumer Staples sector, rankings of US companies

Figures from NU Skin Enterprises, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to NU Skin Enterprises, Inc.